New biosimilar aims to match opdivo in melanoma fight
NCT ID NCT07476326
First seen Mar 25, 2026 · Last updated May 13, 2026 · Updated 10 times
Summary
This study tests whether a new drug called Bmab1700 works like the approved drug Opdivo in people with melanoma (a serious skin cancer) after their tumor has been completely removed by surgery. The study will involve 120 adults with stage IIB to IV melanoma. The main goal is to compare how the body processes each drug and to check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centrul de Oncologie Sfantu Nectarie
Craiova, Romania
Contact
-
Dokuz Eylul University Medical Oncology Hospital Dokuz Eylül Üniverstesi Medikal Onkolji Hastanesi
Konak, Turkey (Türkiye)
Contact
-
Ege University Tulay Aktas Oncology Hospital
Bornova, Turkey (Türkiye)
Contact
-
Excellentis Clinical Trial Consultants
George, South Africa
Contact
-
High Technology Hospital Medcenter
Batumi, Georgia
Contact
-
Hospital Universitario Vall d\'Hebron
Barcelona, Spain
Contact
-
Hospital Universitario Virgen Macarena
Seville, Spain
Contact
-
Hospital Universitario Virgen del Rocío (HUVR)
Seville, Spain
Contact
-
Hospital Virgen de Arrixaca
Murcia, Spain
Contact
-
Institut d'Investigació iInnovació Parc Taulí
Sabadell, Spain
Contact
-
Institute for Oncology and Radiology of Serbia
Belgrade, Serbia
Contact
-
Institute of Clinical Oncology - Lubliana Street
Tbilisi, Georgia
Contact
-
Instituto Oncológico Dr. Rosell (IOR) - Hospital Universitari Quirón Dexeus
Barcelona, Spain
Contact
-
Israel-Georgian Medical Research Clinic Helsicore
Tbilisi, Georgia
Contact
-
JSC Vian
Kutaisi, Georgia
Contact
-
LTD New Hospitals
Tbilisi, Georgia
Contact
-
Military Medical Academy
Belgrade, Serbia
Contact
-
Oncology Institute of Vojvodina
Kamenitz, Serbia
Contact
-
Phoenix Pharma Pty Ltd
Port Elizabeth, South Africa
Contact
-
START Madrid - Hospital Universitario Fundación Jiménez Díaz
Madrid, Spain
Contact
-
The Medical Oncology Center of Rosebank
Johannesburg, South Africa
Contact
-
Todua Clinic
Tbilisi, Georgia
Contact
-
Universities, 1604. Cadde No 9 Ankara, Ankara 06800 Türkiye, Ankara Billkent Şehir Hastanesi
Ankara, Turkey (Türkiye)
Contact
-
University Clinical Center Kragujevac, Clinic for Oncology
Kragujevac, Serbia
Contact
-
University Clinical Center Nis, Clinic for Oncology/
Niš, Serbia
Contact
-
WITS Clinical Research - Wits Donald Gordon Medical Centre
Johannesburg, South Africa
Contact
Conditions
Explore the condition pages connected to this study.